

## DAFTAR PUSTAKA

- Abdul-Rahim, A Quinn, T., Alder, S., Clark, A., Musgrave, S., Langhorne, P., et al. (2015). Derivation and validation of a novel prognostic scale (modified–stroke subtype, Oxfordshire community stroke project classification, age, and prestroke modified rankin) to predict early mortality in acute stroke. *Stroke*, 47(1), pp.74-79.
- Adams H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D and Marsh E. (1993). Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*, 24(1), pp.35-41.
- Al-Nakeeb S, and Clermont G. (2005). Procalcitonin testing has the potential to reduce unnecessary antibiotic use in patients with suspected lower respiratory tract infections. *Critical Care*, 9(3), p.E5.
- Ammori B, Becker, K., Kite, P., Snider, R., Nylén, E., White, J., et al. (2003). Calcitonin precursors in the prediction of severity of acute pancreatitis on the day of admission. *British Journal of Surgery*, 90(2), pp.197-204.
- Andalassari, (2014). *Hubungan Kadar Ferritin Serum Dengan Tingkat Keparahan Stroke Iskemik Akut*. Thesis. Fakultas Kedokteran Universitas Andalas.
- Assicot, M., Bohuon, C., Gendrel, D., Raymond, J., Carsin, H. and Guilbaud, J. (1993). High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet*, 341(8844), pp.515-518.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, (2013). *Riset Kesehatan Dasar*. Jakarta: Kementerian Kesehatan RI.
- Becker, K., Snider, R. and Nylén, E. (2009). Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *British Journal of Pharmacology*, 159(2), pp.253-264.
- Benjamin, E., Blaha, M., Chiuve, S., Cushman, M., Das, S., Deo, R., et al. (2017). Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. *Circulation*, 135(10), pp.e146-e603.
- Brennan, A, Won Suh, S., Joon Won, S., Narasimhan, P., Kauppinen, T., Lee, H., et al. (2009). NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. *Nature Neuroscience*, 12(7), pp.857-863.
- Briel, M., et al. (2008). Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. *Arch Intern Med*, 168(18), p.2000.
- Brouns, R. and De Deyn, P. (2009). The complexity of neurobiological processes in acute ischemic stroke. *Clinical Neurology and Neurosurgery*, 111(6), pp.483-495.
- Caplan, L. (2009). *Caplan's stroke*. Philadelphia: Elsevier/Saunders.

- Chauhan, A., Moser, H. and McCullough, L. (2017). Sex differences in ischaemic stroke: potential cellular mechanisms. *Clinical Science*, 131(7), pp.533-552.
- Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M., Huber, P., Tamm, M., et al. (2004). Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. *The Lancet*, 363(9409), pp.600-607.
- Cincura, C., Pontes-Neto, O., Neville, I., Mendes, H., Menezes, D., Mariano, D., et al. (2009). Validation of the national institutes of health stroke scale, modified rankin scale and barthel index in brazil: the role of cultural adaptation and structured interviewing. *Cerebrovasc Dis*, 27(2), pp.119-122.
- Deb, P., Sharma, S. and Hassan, K. (2010). Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology*, 17(3), pp.197-218.
- Deng, W., Shen, R., Li, M. and Teng, J. (2014). Relationship between procalcitonin serum levels and functional outcome in stroke patients. *Cellular and Molecular Neurobiology*, 35(3), pp.355-361.
- Dirnagl, U., Iadecola, C. and Moskowitz, M. (1999). Pathobiology of ischaemic stroke: an integrated view. *Trends in Neurosciences*, 22(9), pp.391-397.
- Doehner, W., Schenkel, J., Anker, S., Springer, J. and Audebert, H. (2012). Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. *European Heart Journal*, 34(4), pp.268-277.
- Dubos, F., Korczowski, B., Aygun, D., Martinot, A., Prat, C., Galetto-Lacour, A., et al. (2008). Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children. *Arch Pediatr Adolesc Med*, 162(12), p.1157.
- Emre, U., Ergün U, Ünal A, Coşkun O, Atasoy H, Yildiz H., et al. (2007). The role of acute phase reactants in acute ischemic stroke. *J.Neurol.Sci.[Turk]*, 24(1)10, pp.64-69.
- Ernst, A., Morgenthaler, N., Buerger, K., Dodel, R., Noelker, C., Sommer, N., et al. (2007). Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. *Journal of Neuroimmunology*, 189(1-2), pp.169-174.
- Fattore, G., Torbica, A., Susi, A., Giovanni, A., Benelli, G., Gozzo, et al. (2012). The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study. *BMC Neurology*, 12(1), p.137.
- Gendrel, D., Raymond, J., Assicot, M., Moulin, F., Iniguez, J., Lebon, P., et al. (1997). Measurement of procalcitonin levels in children with bacterial or viral meningitis. *Clinical Infectious Diseases*, 24(6), pp.1240-1242.

- George, P. and Steinberg, G. (2015). Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments. *Neuron*, 87(2), pp.297-309.
- Greer, D., Homma, S. And Furie, K. (2011). Cardiac Diseases. In: J. Mohr, P. Wolf, J. Grotta, M. Moskowitz, M. Mayberg And R. Von Kummer, Ed., *Stroke: Pathophysiology, Diagnosis, And Management*, 5th Ed. Philadelphia: Elsevier Saunders, Pp.814-827.
- Hankey, G. (2006). Potential new risk factors for ischemic stroke: what is their potential?. *Stroke*, 37(8), pp.2181-2188.
- Hatzistilianou, M. (2010). Diagnostic and prognostic role of procalcitonin in infections. *The Scientific World JOURNAL*, 10, pp.1941-1946.
- He, J., Gu, D., Wu, X., Reynolds, K., Duan, X., Yao, C., et al. (2005). Major causes of death among men and women in china. *New England Journal of Medicine*, 353(11), pp.1124-1134.
- Heath, V. (2009). Procalcitonin assay shows promise. *Nat Rev Endocrinol*, 5(4), pp.184-184.
- Hoffmann, G., Czechowski, M., Schloesser, M. and Schobersberger, W. (2002). Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. *Critical Care Medicine*, 30(9), pp.2091-2095.
- Huang, J., Upadhyay, U. and Tamargo, R. (2006). Inflammation in stroke and focal cerebral ischemia. *Surgical Neurology*, 66(3), pp.232-245.
- Iadecola, C. and Anrather, J. (2011). The immunology of stroke: from mechanisms to translation. *Nature Medicine*, 17(7), pp.796-808.
- Kafetzis, D., Velissariou, I., Nikolaidis, P., Sklavos, M., Maktabi, M., Spyridis, G., et al. (2005). Procalcitonin as a predictor of severe appendicitis in children. *Eur J Clin Microbiol Infect Dis*, 24(7), pp.484-487.
- Kang, H., Lim, S., Suh, H. and Liew, D. (2011). Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study. *BMC Public Health*, 11(1), p.646.
- Kasner, S. (2006). Clinical interpretation and use of stroke scales. *The Lancet Neurology*, 5(7), pp.603-612.
- Katan, M., Moon Y, DeRosa J, Paik M, Mueller B, Herklotz R, et al. (2014). Procalcitonin, copeptin and midregional pro-atrial natriuretic peptide as markers of ischemic stroke risk: The Northern Manhattan Study. *International Stroke Conference Oral Abstracts*.
- Katan, M., Moon, Y., von Eckardstein, A., Spanaus, K., DeRosa, J., Gutierrez, J., et al. (2017). Procalcitonin and Midregional Proatrial Natriuretic Peptide as Biomarkers of Subclinical Cerebrovascular Damage. *Stroke*, 48(3), pp.604-610.

- Kocazeybek, B., Küçükoğlu, S. and Öner, Y. (2003). Procalcitonin and c-reactive protein in infective endocarditis: correlation with etiology and prognosis. *Chemotherapy*, 49(1-2), pp.76-84.
- Kramer, D., Fujii, T., Ohiorhenuan, I. and Liu, C. (2015). Cortical spreading depolarization: Pathophysiology, implications, and future directions. *Journal of Clinical Neuroscience*.
- Krishnamurthi, R., deVeber, G., Feigin, V., Barker-Collo, S., Fullerton, H., Mackay, M., et al. (2015). Stroke prevalence, mortality and disability-adjusted life years in children and youth aged 0-19 years: data from the global and regional burden of stroke 2013. *Neuroepidemiology*, 45(3), pp.177-189.
- Krishnamurthi, R., deVeber, G., Feigin, V., Barker-Collo, S., Fullerton, H., Mackay, M., et al. (2015a). Stroke prevalence, mortality and disability-adjusted life years in adults aged 20-64 years in 1990-2013: data from the global burden of disease 2013 study. *Neuroepidemiology*, 45(3), pp.190-202.
- Kuklina, E., Tong, X., George, M. and Bansil, P. (2012). Epidemiology and prevention of stroke: a worldwide perspective. *Expert Review of Neurotherapeutics*, 12(2), pp.199-208.
- Lakhan, S., Kirchgessner, A. and Hofer, M. (2009). Inflammatory mechanisms in ischemic stroke: therapeutic approaches. *Journal of Translational Medicine*, 7(1), p.97.
- Le Moullec, J., Jullienne, A., Chenais, J., Lasmoles, F., Guliana, J., Milhaud, G. et al. (1984). The complete sequence of human procalcitonin. *FEBS Letters*, 167(1), pp.93-97.
- Leli, C., Cardaccia, A., Ferranti, M., Cesarini, A., D'Alò, F., Ferri, C., et al. (2014). Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis. *Scandinavian Journal of Infectious Diseases*, 46(11), pp.745-752.
- Li, Y. and Liu, X. (2015). Serum levels of procalcitonin and high sensitivity C-reactive protein are associated with long-term mortality in acute ischemic stroke. *Journal of the Neurological Sciences*, 352(1-2), pp.68-73.
- Lin, J. and Yap, S. (2015). *Procalcitonin: Reference Range, Interpretation, Collection and Panels*. [online] Emedicine.medscape.com. Available at: <http://emedicine.medscape.com/article/2096589-overview> [Accessed 24 Dec. 2015].
- Linscheid, P., Seboek, D., Nysten, E., Langer, I., Schlatter, M., Becker, K., et al. (2003). In vitro and in vivo calcitonin i gene expression in parenchymal cells: a novel product of human adipose tissue. *Endocrinology*, 144(12), pp.5578-5584.
- Linscheid, P., Seboek, D., Schaer, D., Zulewski, H., Keller, U. and Müller, B. (2004). Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes\*. *Critical Care Medicine*, 32(8), pp.1715-1721.

- Liu, H., Guo, J., Geng, Y. and Su, L. (2015). Procalcitonin: present and future. *Irish Journal of Medical Science (1971 -)*, 184(3), pp.597-605.
- Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*, 380(9859), pp.2095-2128.
- Luengo-Fernandez, R., Gray, A. and Rothwell, P. (2012). A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke. *Stroke*, 43(12), pp.3343-3351.
- Mackay, J., Mensah, G., Mendis, S. and Greenlund, K. (2004). *The atlas of heart disease and stroke*. Geneva: World Health Organization.
- Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U. et al. (2011). Stroke and the immune system: from pathophysiology to new therapeutic strategies. *The Lancet Neurology*, 10(5), pp.471-480.
- Maier, M., Wutzler, S., Lehnert, M., Szermutzky, M., Wyen, H., Bingold, T., et al. (2009). Serum procalcitonin levels in patients with multiple injuries including visceral trauma. *The Journal of Trauma: Injury, Infection, and Critical Care*, 66(1), pp.243-249.
- Mansour, O., Megahed, M. and Abd Elghany, E. (2015). Acute ischemic stroke prognostication, comparison between Glasgow Coma Score, NIHSS Scale and Full Outline of UnResponsiveness Score in intensive care unit. *Alexandria Journal of Medicine*, 51(3), pp.247-253.
- Maruna, P., Nedělníková, K. and Gürlich, R. (2000). Physiology and genetics of procalcitonin. *Physiol Res*, 49(Suppl 1), pp.S57-S61.
- Mehndiratta, M., Khan, M., Mehndiratta, P. and Wasay, M. (2014). Stroke in Asia: geographical variations and temporal trends. *Journal of Neurology, Neurosurgery & Psychiatry*, 85(12), pp.1308-1312.
- Meisner, M., Lohs, T., Huettemann, E., Schmidt, J., Hueller, M. and Reinhart, K. (2001). The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. *European Journal of Anaesthesiology*, 18(2), pp.79-87.
- Meisner, M., Tschakowsky, K., Hutzler, A., Schüttler, J. and Schick, C. (1998). Postoperative plasma concentrations of procalcitonin after different types of surgery. *Intensive Care Med*, 24(7), pp.680-684.
- Meng, X., Li, N., Guo, D., Pan, S., Li, H. and Yang, C. (2014). High plasma glutamate levels are associated with poor functional outcome in acute ischemic stroke. *Cellular and Molecular Neurobiology*, 35(2), pp.159-165.
- Mir, M., Al-Baradie, R. and Alhussainawi, M. (2014). Pathophysiology Of Stroke. In: M. Mir, R. Al-Baradie and M. Alhussainawi, ed., *Recent Advances in Stroke Therapeutics*, 1st ed. New York: Nova, pp.1-53.

- Misbach, J. and Ali, W. (2001). Stroke in Indonesia: A first large prospective hospital-based study of acute stroke in 28 hospitals in Indonesia. *Journal of Clinical Neuroscience*, 8(3), pp.245-249.
- Miyakis, S., Georgakopoulos, P., Kiagia, M., Papadopoulou, O., Pefanis, A., Gonis, A. et al. (2004). Serial serum procalcitonin changes in the prognosis of acute stroke. *Clinica Chimica Acta*, 350(1-2), pp.237-239.
- Moskowitz, M., Lo, E. and Iadecola, C. (2010). The Science of Stroke: Mechanisms in Search of Treatments. *Neuron*, 67(2), pp.181-198.
- Moya, F., Nieto, A. And R-Candela, J. (1975). Calcitonin biosynthesis: evidence for a precursor. *Eur J Biochem*, 55(2), pp.407-413.
- Mozaffarian, D., Benjamin, E., Go, A., Arnett, D., Blaha, M., Cushman, M., et al. (2014). Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation*, 131(4), pp.e29-e322.
- Ng, C., Toh, M., Ng, J. and Ko, Y. (2015). Direct medical cost of stroke in Singapore. *Int J Stroke*, 10, pp.75-82.
- Nylen, E., Arifi, A., Becker, K., Snider, R. and Alzeer, A. (1997). Effect of classic heatstroke on serum procalcitonin. *Critical Care Medicine*, 25(8), pp.1362-1365.
- Nylén, E., O'Neill, W., Jordan, M., Snider, R., Moore, C., Lewis, M., et al. (1992). Serum Procalcitonin as an Index of Inhalation Injury in Burns. *Hormone and Metabolic Research*, 24(09), pp.439-442.
- Nylén, E., Snider, R., Thompson, K., Rohatgi, P. and Becker, K. (1996). Pneumonitis-associated hyperprocalcitoninemia. *The American Journal of the Medical Sciences*, 312(1), pp.12-18.
- O'connor, E., Venkatesh, B., Lipman, J., Mashongonyika, C. And Hall, J. (2001). Procalcitonin in critical illness. *Critical Care and Resuscitation*, 3, pp.236-243.
- Oberhoffer, M., M., Stonans, I., Russwurm, S., Stonane, E., Vogelsang, H., Junker, U., et al. (1999). Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. *Journal of Laboratory and Clinical Medicine*, 134(1), pp.49-55.
- O'Donnell, M., Xavier, D., Liu, L., Zhang, H., Chin, S., Rao-Melacini, P., et al. (2010). Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *The Lancet*, 376(9735), pp.112-123.
- Oemijati, S., Setiabudy, R. and Budijanto, A. (1987). *Pedoman Etik penelitian kedokteran Indonesia*. Jakarta: Balai Penerbit FKUI.
- Ofengeim, D., Miyawaki, T. and Zukin, R. (2011). Molecular and Cellular Mechanisms of Ischemia-Induced Neuronal Death. In: J. Mohr, P. Wolf, J.

- Grotta, M. Moskowitz, M. Mayberg and R. Kummer, ed., *Stroke, Pathophysiology, Diagnosis and Management*, 5th ed. Philadelphia: Elsevier Saunders, pp.75-106.
- Persson, J., Ferraz-Nunes, J. and Karlberg, I. (2012). Economic burden of stroke in a large county in Sweden. *BMC Health Services Research*, 12(1), p.341.
- Preas II, H., et al. (2001). Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. *The Journal of Infectious Diseases*, 184(3), pp.373-376.
- Ritzel, R., Capozzi, L. and McCullough, L. (2013). Sex, stroke, and inflammation: The potential for estrogen-mediated immunoprotection in stroke. *Hormones and Behavior*, 63(2), pp.238-253.
- Russwurm, S., Wiederhold, M., Oberhoffer, M., Stonans, I., Zipfel, P. and Reinhart, K. (1999). Molecular aspects and natural source of procalcitonin. *Clinical Chemistry and Laboratory Medicine*, 37(8).
- Sacco, R., Kasner, S., Broderick, J., Caplan, L., Connors, J., Culebras, A., et al. (2013). An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, 44(7), pp.2064-2089.
- Schroeder, S., Hochreiter, M., Koehler, T., Schweiger, A., Bein, B., Keck, F. et al. (2008). Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbecks Arch Surg*, 394(2), pp.221-226.
- Shahar, E., Chambless, L., Rosamond, W., Boland, L., Ballantyne, C., McGovern, P. et al. (2003). Plasma Lipid Profile and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study. *Stroke*, 34(3), pp.623-631.
- Silverman, I. and Rymer, M. (2009). *Ischemic stroke*. Oxford: Clinical Pub.
- Simon, L., Gauvin, F., Amre, D., Saint-Louis, P. and Lacroix, J. (2004). Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clinical Infectious Diseases*, 39(2), pp.206-217.
- Simon, P., Milbrandt, E. and Emler, L. (2008). Procalcitonin-guided antibiotics in severe sepsis. *Critical Care*, 12(6), p.309.
- Strong, K., Mathers, C. and Bonita, R. (2007). Preventing stroke: saving lives around the world. *The Lancet Neurology*, 6(2), pp.182-187.
- Taylor, T., Davis, P., Torner, J., Holmes, J., Meyer, J. and Jacobson, M. (1996). Lifetime cost of stroke in the United States. *Stroke*, 27(9), pp.1459-1466.
- Tian, D., Zhang, S., He, X. and Liu, H. (2015). Serum procalcitonin as a diagnostic marker in acute ischemic stroke. *NeuroReport*, 26(1), pp.33-37.

- von Heimburg, D., Stieghorst, W., Khorram-Sefat, R. and Pallua, N. (1998). Procalcitonin—a sepsis parameter in severe burn injuries. *Burns*, 24(8), pp.745-750.
- Vos T, Barber, R., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., et al. (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*, 386(9995), pp.743-800.
- Wacker, C., Prkno, A., Brunkhorst, F. and Schlattmann, P. (2013). Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, 13(5), pp.426-435.
- Wang, C., Gao, L., Zhang, Z., Li, Y., Yang, Y., Chang, T., et al. (2015). Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity c-reactive protein in patients with ischemic stroke. *Molecular Neurobiology*, 53(3), pp.1509-1517.
- Wei, J., Verity, A., Garle, M., Mahajan, R. and Wilson, V. (2008). Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. *British Journal of Anaesthesia*, 100(5), pp.612-621.
- Whiteley, W., Chong, W., Sengupta, A. and Sandercock, P. (2009). Blood markers for the prognosis of ischemic stroke: a systematic review. *Stroke*, 40(5), pp.e380-e389.
- Who.int, (2015). *WHO | Metrics: Disability-Adjusted Life Year (DALY)*. [online] Available at: [http://www.who.int/healthinfo/global\\_burden\\_disease/metrics\\_daly/en/](http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/) [Accessed 19 Nov. 2015].
- Wolf, P. and Kanel, W. (2011). Epidemiology of Stroke. In: J. Mohr, P. Wolf, J. Grotta, M. Moskowitz, M. Mayberg and R. Kummer, ed., *Stroke, Pathophysiology, Diagnosis and Management*, 5th ed. Philadelphia: Elsevier Saunders, pp.198-218.
- Xing, C., Arai, K., Lo, E. and Hommel, M. (2012). Pathophysiologic cascades in ischemic stroke. *Int J Stroke*, 7(5), pp.378-385.
- Youman, P., Wilson, K., Harraf, F. and Kalra, L. (2003). The economic burden of stroke in the United Kingdom. *Pharmacoeconomics*, 21(Supplement 1), pp.43-50.